Beijing Gene Key Life Technology Co., Ltd clinical trials
The registry lists 7 studies whose lead sponsor is Beijing Gene Key Life Technology Co., Ltd. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 4, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 7studies on the registry
- 5open to participants now
- 2reach primary completion within a year
Get an email when these change. Save the Beijing Gene Key Life Technology Co., Ltd studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 4 programmes
Each counted once: 4 with a study Beijing Gene Key Life Technology Co., Ltd leads registered in the last two years.
The 4 programmes — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or next readout.
New in the registry
A programme's first Beijing Gene Key Life Technology Co., Ltd study in the last 90 days, by the day it was submitted.
- Oct 16GKL-006Allo · Spondylitis, AnkylosingPhase 1
Moved up a phase
Beijing Gene Key Life Technology Co., Ltd's first study at a higher phase in the last 90 days, of a programme already under way.
None in the last 90 days.
“Registry” is the highest phase of Beijing Gene Key Life Technology Co., Ltd’s own registered studies; Beijing Gene Key Life Technology Co., Ltd’s own pipeline document is not read yet. “Next readout” is the earliest primary completion date still ahead among its live studies, as the registry states it (most are estimates). Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Beijing Gene Key Life Technology Co., Ltd’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
2 of Beijing Gene Key Life Technology Co., Ltd’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- 1MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- 1SSep
- OOct
- NNov
All 2
Add all 2 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
- A Study of GKL-006 Injection in Patients With Advanced Pancreatic CancerNov 4, 2026NCT07777211
Newly registered1
- A Study of GKL-006Allo Injection in Patients With Ankylosing SpondylitisNov 4, 2026NCT07915544
All 7 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 24
- 325
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Beijing Gene Key Life Technology Co., Ltd.
- Beijing Gene Key Life Technology Co., Ltd7 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 7 of 7.
- A Study of GKL-006 Injection in Patients With Advanced Pancreatic CancerRecruitingNCT07777211Phase 1/2
- A Study of GKL-006Allo Injection in Patients With Ankylosing SpondylitisNot yet recruitingNCT07915544Phase 1
- Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)Not yet recruitingNCT07706855Phase 1/2
- GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Phase 2
- GKL-006Allo Injection in Patients With Advanced Solid TumorsNot yet recruitingNCT07704515Phase 1
- Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular CarcinomaCompletedNCT07845266Phase 1
- A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07713290Phase 1